Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower plasma Lp(a) concentrations exist. We have assessed the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation antisense drug designed to reduce the synthesis of apolipoprotein(a) (apo[a]) in the liver.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Oct 10 2015

Volume: 386

Issue: 10002

Affiliations

[1 ] University of California San Diego, La Jolla, CA, USA; Isis Pharmaceuticals, Carlsbad, CA, USA. Electronic address: stsimikas@ucsd.edu.

[2 ] Isis Pharmaceuticals, Carlsbad, CA, USA.

[3 ] University of Washington, Seattle, WA, USA.

[4 ] University of California San Diego, La Jolla, CA, USA.

Article

Publisher Item ID: S0140-6736(15)61252-1

DOI: 10.1016/S0140-6736(15)61252-1

PubMed ID: 26210642

SO-VID: 6e586d7a-90cb-4ac3-aa6f-8934c8474791

History

Data availability:

Comments

Comment on this article

scite_

Cited by 123

See all cited by

- Version 1